Aura Biosciences, Inc.

NASDAQ:AURA

Biotechnology

Healthcare
$7.15 -1.43%

-$0.09 today

Market cap
$744.13M
Beta
0.39
P/E (TTM)
-3.7
EPS (TTM)
-$1.67
52W Low $4.73High $9.54

Volume 0.63M

Average 0.52M

Returns on capital

Aura Biosciences, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-77.6%

avg -59.3%

ROIC

-73.1%

avg -58.2%

ROA

-62.7%

avg -50.6%

Analysis

ROA is currently the strongest return metric at -62.7% versus its period average of -50.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jill Hopkins

Chief Medical Officer & President of Research and DevelopmentUSD 792.75K61——

Susan Abu-Absi

Chief Operating OfficerUSD 592.5K—134.51K0.21%

Alex Dasalla

Head of Investor Relations & Corporate Communications————

Anthony Daniels

Vice President & Therapeutic Area of Head Ocular Oncology————

Patrick Nealon

Senior Vice President of Clinical Development Operations————

Amy Elazzouzi

Senior Vice President of Finance, Treasurer and Secretary—5246.46K0.07%

Erica Kratz

Chief Regulatory & Quality Officer——100.89K0.16%

Julie Person

Chief People Officer—52107.61K0.17%

Natalie C. Holles

President, CEO & Director—53600.12K0.93%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

10

$39.83M

Net Transaction Value

−$39.83M

Net selling

Most Active

Kilroy Conor

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jun 16, 26

Gibney Anthony S

Direct

Sell$82.3K
May 7, 26

Matrix Capital Management Company, LP

Indirect

Sell$39M
Apr 16, 26

Kilroy Conor

Direct

Sell$82.4K
Feb 17, 26

Kilroy Conor

Direct

Sell$61K
Feb 17, 26

Plavsic Mark

Direct

Sell$80.2K
Feb 17, 26

Hopkins Janet Jill

Direct

Sell$103.2K
Feb 17, 26

Elazzouzi Amy

Direct

Sell$43.3K
Feb 17, 26

de los Pinos Elisabet

Direct

Sell$241.1K
Jan 20, 26

Elazzouzi Amy

Direct

Sell$7.7K
Jan 20, 26

de los Pinos Elisabet

Direct

Sell$82.3K

Summary

Insiders reported 0 buys worth $0.00 and 10 sells worth $39.83M over the last 12 months. That adds up to net selling of $39.83M. Kilroy Conor was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Aura Biosciences, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about AURA's management, answered from reported figures.

Who manages AURA?

Aura Biosciences, Inc. (AURA) lists 9 active executives. The top listed executive is Alex Dasalla, Head of Investor Relations & Corporate Communications.

Are AURA insiders buying or selling?

Recent insider activity shows net buying of $30.32M.